Filing Flows › Precision Biosciences (DTIL) › Q3 FY26
Precision Biosciences (DTIL) Q3 FY26 earnings results (third quarter fiscal 2026)
10-Q filed May 5, 2026
Precision Biosciences (DTIL) reported revenue of $10.8M for the third quarter fiscal 2026 (Q3 FY26), up 374-fold from a year earlier and -68% from the quarter before. Operating margin was -83.7%, net loss $18.4M (170.2% of revenue).
Precision Biosciences, Q3 FY26: revenue $10.8M (374× year over year), operating margin -83.7%, net loss $18.4M, operating cash flow −$11.9M. The chart follows the revenue to costs, profit and cash.
| Q3 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $10.8M | -68% | 374× |
| Operating profit | −$9.1M | -173% | — |
| Net earnings | −$18.4M | -192% | — |
| Operating cash flow | −$11.9M | — | — |
What changed
Revenue was $10.8M in Q3 FY26, up 37272% year over year and down 68% from the previous quarter.
Operating costs exceeded revenue by $9.1M, an operating margin of -83.7%. Total costs fell 10% while revenue rose 37272%. The quarter ended with a net loss of $18.4M, after a profit of $20.1M the previous quarter. Net interest and other expense of $9.4M was the main reason.
Operating cash flow was −$11.9M. Non-cash charges added back $299K of depreciation and amortization and $1.5M of share-based compensation. Working capital and other items added $4.7M. Capital expenditures of $18K exceeded it, leaving free cash flow of −$12.0M.
Questions
What was Precision Biosciences' revenue in the third quarter fiscal 2026?
Precision Biosciences (DTIL) reported revenue of $10.8M for the third quarter fiscal 2026 (Q3 FY26), up 374-fold from a year earlier and -68% from the quarter before.
Was Precision Biosciences profitable in the third quarter fiscal 2026?
Operating loss was $9.1M (-83.7% of revenue) and net loss $18.4M.